TuHURA Biosciences, Inc. (HURA) vs MaxCyte, Inc. (MXCT)
A side-by-side comparison of TuHURA Biosciences, Inc. and MaxCyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
HURA
TuHURA Biosciences, Inc.
$1.92HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT
MXCT
MaxCyte, Inc.
$1.06HealthcareDelayed quote: Oct 6, 2026, 12:05 PM EDT
Total return — HURA vs MXCT
growth of $100 · dividends reinvested · last 5yHURA -97.6% (-52.5%/yr)MXCT -93.6% (-42.4%/yr)MXCT compounded faster over this window
HURA MXCT
HURA vs MXCT: by the numbers
- •HURA is the larger company ($122M vs $113M market cap).
- •Both run net losses; HURA's is the smaller (0.00% vs -114.77% net margin).
Metrics side by side
Valuation
| Metric | HURA | MXCT |
|---|---|---|
| P/S ratio | N/A | 3.64 |
| P/B ratio | 6.71 | 0.71 |
Profitability
| Metric | HURA | MXCT |
|---|---|---|
| Gross margin | 0.00% | 79.43% |
| Operating margin | 0.00% | -137.12% |
| Net margin | 0.00% | -114.77% |
| ROE | -165.57% | -22.45% |
| ROIC | -137.40% | -19.83% |
Growth (annualized)
| Metric | HURA | MXCT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 1.46% |
| Total return CAGR (5Y) | -45.49% | -37.32% |
Frequently asked
- How have HURA and MXCT total returns compared?
- Over the past 5 years, HURA delivered -45.49% and MXCT delivered -37.32% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.